Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01786096 · ClinicalTrials.gov registry record · Phase 1
A Safety Study of SGN-CD19A for Leukemia and Lymphoma
A Phase 1 study, sponsored by Seagen.
- Completed
- Registry status
- Phase 1
- Development phase
- 92
- Enrollment target
NCT01786096 is a Phase 1 study that has completed, run by Seagen. The registered enrollment target is 92 participants.
The verdict
NCT01786096, a Phase 1 study, has completed, sponsored by Seagen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 92 participants
- Enrollment target
Study Summary
This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL).
Interventions
- DRUG SGN-CD19A
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 92 participants |
| Start Date | 2013-02 |
| Est. Completion | 2017-05-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01786096
The ClinicalTrials.gov registry entry for NCT01786096 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 92 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Seagen, which has 84 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which SGN-CD19A is the first listed.
NCT01786096 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01786096 about?
NCT01786096 is a clinical study titled "A Safety Study of SGN-CD19A for Leukemia and Lymphoma". This is a phase 1, open-label, dose-escalation, multicenter study to evaluate the safety and tolerability of SGN-CD19A in adult and pediatric patients with relapsed or refractory B-lineage acute lymphoblastic leukemia (B-ALL), Burkitt lymphoma or leukemia, or B-lineage lymphoblastic lymphoma (B-LBL)...
What is the current status of trial NCT01786096?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 92 participants. The study started on 2013-02. Estimated completion is 2017-05-30.
What interventions are being tested in trial NCT01786096?
The interventions under investigation include: SGN-CD19A (DRUG).
Who is sponsoring clinical trial NCT01786096?
This trial is sponsored by Seagen, which has 84 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.